{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T22:11:38Z","timestamp":1765404698504,"version":"3.46.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-cot.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Orthopaedics and Trauma"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jcot.2025.103155","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T23:56:11Z","timestamp":1754438171000},"page":"103155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Use of Ceftaroline for prosthetic joint infections and spinal hardware infections"],"prefix":"10.1016","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4977-0968","authenticated-orcid":false,"given":"James B.","family":"Doub","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander R.","family":"Cain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jcot.2025.103155_bib1","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40272-021-00474-y","article-title":"Ceftaroline fosamil for treatment of pediatric complicated skin and soft tissue infections and community-acquired pneumonia [published correction appears in","volume":"23","author":"Esposito","year":"2021","journal-title":"Paediatr Drugs"},{"issue":"170","key":"10.1016\/j.jcot.2025.103155_bib2","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0117-2023","article-title":"Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant Staphylococcus aureus pneumonia","volume":"32","author":"Torres","year":"2023","journal-title":"Eur Respir Rev"},{"issue":"4","key":"10.1016\/j.jcot.2025.103155_bib3","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1592\/phco.30.4.375","article-title":"Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens","volume":"30","author":"Steed","year":"2010","journal-title":"Pharmacotherapy"},{"issue":"8","key":"10.1016\/j.jcot.2025.103155_bib4","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1097\/INF.0000000000001191","article-title":"A multicenter, randomized, observer-blinded, active-controlled study to evaluate the safety and efficacy of ceftaroline versus comparator in pediatric patients with acute bacterial skin and skin structure infection","volume":"35","author":"Korczowski","year":"2016","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"10.1016\/j.jcot.2025.103155_bib5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1473-3099(14)71018-7","article-title":"Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial","volume":"15","author":"Zhong","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"Suppl 3","key":"10.1016\/j.jcot.2025.103155_bib6","first-page":"iii19","article-title":"FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"File","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 4","key":"10.1016\/j.jcot.2025.103155_bib7","first-page":"iv41","article-title":"Canvas 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","author":"Corey","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.jcot.2025.103155_bib8","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cis803","article-title":"Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the infectious diseases society of America","volume":"56","author":"Osmon","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.jcot.2025.103155_bib9","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1093\/cid\/ciae436","article-title":"State-of-the-Art review: diagnosis and management of spinal implant infections","volume":"79","author":"Tai","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.jcot.2025.103155_bib10","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.cmi.2024.11.022","article-title":"Ceftaroline for bloodstream infections caused by methicillin-resistant Staphylococcus aureus: a multicentre retrospective cohort study","volume":"31","author":"Villa","year":"2025","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"10.1016\/j.jcot.2025.103155_bib11","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/jac\/dkw062","article-title":"High incidence of neutropenia in patients with prolonged ceftaroline exposure","volume":"71","author":"Furtek","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.jcot.2025.103155_bib12","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx084","article-title":"Ceftaroline for severe methicillin-resistant Staphylococcus aureus infections: a systematic review","volume":"4","author":"Cosimi","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"10.1016\/j.jcot.2025.103155_bib13","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ijantimicag.2013.07.005","article-title":"Ceftaroline for meticillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature","volume":"42","author":"Polenakovik","year":"2013","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.jcot.2025.103155_bib14","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s10156-012-0449-9","article-title":"The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients","volume":"19","author":"Lin","year":"2013","journal-title":"J Infect Chemother"},{"issue":"1","key":"10.1016\/j.jcot.2025.103155_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2022.115820","article-title":"Update on the in vitro activity of ceftaroline against Staphylococcus aureus from United States (US) medical centers stratified by infection type (2018-2020)","volume":"105","author":"Sader","year":"2023","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"9","key":"10.1016\/j.jcot.2025.103155_bib16","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00485-18","article-title":"Ceftaroline resistance by clone-specific polymorphism in penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus","volume":"62","author":"Lee","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.jcot.2025.103155_bib17","doi-asserted-by":"crossref","first-page":"6668","DOI":"10.1128\/AAC.03622-14","article-title":"PBP2a mutations causing high-level ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates","volume":"58","author":"Long","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.jcot.2025.103155_bib18","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/INF.0000000000001171","article-title":"Evolution of ceftaroline-resistant mrsa in a child with cystic fibrosis following repeated antibiotic exposure","volume":"35","author":"Cannavino","year":"2016","journal-title":"Pediatr Infect Dis J"},{"issue":"8","key":"10.1016\/j.jcot.2025.103155_bib19","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1007\/s00590-023-03609-8","article-title":"Effective use of a two-dose regimen of dalbavancin to treat prosthetic joint infections and spinal hardware infections","volume":"33","author":"Doub","year":"2023","journal-title":"Eur J Orthop Surg Traumatol"},{"key":"10.1016\/j.jcot.2025.103155_bib20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jgar.2021.03.026","article-title":"Dalbavancin treatment for prosthetic joint infections in real-life: a national cohort study and literature review","volume":"25","author":"Matt","year":"2021","journal-title":"J Glob Antimicrob Resist"}],"container-title":["Journal of Clinical Orthopaedics and Trauma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S097656622500253X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S097656622500253X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T22:08:35Z","timestamp":1765404515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S097656622500253X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":20,"alternative-id":["S097656622500253X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcot.2025.103155","relation":{},"ISSN":["0976-5662"],"issn-type":[{"type":"print","value":"0976-5662"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of Ceftaroline for prosthetic joint infections and spinal hardware infections","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Orthopaedics and Trauma","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcot.2025.103155","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"103155"}}